Peptides DB
Research-centric peptide and protocol reference hub

Orforglipron (LY-3502970) record · updated 5h ago

Metabolic & appetiteSleep & circadianGrade A · human clinicalResearch use only
All 26 studiesJump to the evidenceCompare
What is Orforglipron (LY-3502970) used for?

Orforglipron (LY-3502970) is an investigational oral small-molecule GLP-1 receptor agonist studied for type 2 diabetes and obesity, offering pill-based dosing without injection.

How it works: GLP-1 receptor agonist

Primarily researched for · Metabolic & appetiteRoute · Oral

Development stage

where Orforglipron (LY-3502970) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 49 registered trials. It describes the research record, not a recommendation.

Identity
NameOrforglipron (LY-3502970)
Chain length—
Molecular weight883 Da
FormulaC48H48F2N10O5
Structure typeNot established
ClassMetabolic
Research levelFDA Approved
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 137319706. No verified residue count for this compound.

Pharmacology
MechanismGLP-1 receptor agonist
RouteOral
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies26
Human / animal / cellular9 / 0 / 2
Highest trial phasePhase 3
Years covered2023–2026
Latest study3d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

26 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.
FindingPercentage body weight change p < 0.00001.
review2026Full text read0.90
Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.
Finding-48.6% to -59.4% relative reduction in T2D risk score vs placebo (-10.5%; p<0.0001; HR-range 0.43-0.55)
Human2026Full text read0.80
Orforglipron and the Kidney: A Promise or Disappointment? The Need for Trials Examining Renal Outcomes.
FindingNot reported in abstract.
review—Full text read0.80
Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.
FindingFor a representative 50-year-old man with T2D, the PCE estimated a 10-year RRR of 16.8% at the 36 mg dose, while PREVENT projected an RRR of 31.4% at the same dose.
review2023Full text read0.80
Variant-specific pharmacophoric shifts in glucagon-like peptide-1 receptor-orforglipron complexes revealed by Boltz-2 co-folding and membrane molecular dynamics.
FindingG168S exhibited the strongest binding (-117.18 kcal/mol)
In vitro2026Full text read0.80
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Finding-12.4% placebo-subtracted weight loss for orforglipron (95% CI, -15.1% to -9.7%)
review2024Full text read0.90
Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.
Finding339 participants (85%, 95% CI 80·7-87·8) had at least one treatment-emergent adverse event (TEAE).
Human2023Full text read0.80
Safety and tolerability of orforglipron in Japanese people with type 2 diabetes.
TakeawayNot reported in abstract.
—2026Title only0.10
Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.
TakeawayNot reported in abstract.
Human2026Title only0.10
Safety and tolerability of orforglipron in Japanese people with type 2 diabetes.
TakeawayNot reported in abstract.
—2026Title only0.10
Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.
Finding-7.9% weight change with orforglipron 5.5 mg vs placebo at Week 72, n=118, p<0.001.
Human2026Full text read0.80
Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials.
FindingSix (0.1%) orforglipron-treated participants had ALT or AST ≥ 3 × ULN and TBIL ≥ 2 × ULN.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Orforglipron (LY-3502970) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Orforglipron (LY-3502970) is discussed should be drawn from it.